Cantuzumab mertansine

Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792) ) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].

Product Specifications

CAS Number

[400010-39-1]

Product Name Alternative

SB-408075; huC242-DM1

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cantuzumab-mertansine.html

Purity

96.02

Solubility

10 mM in DMSO

Smiles

[Cantuzumabmertansine]

Molecular Weight

150000 (average)

References & Citations

[1]Paul R Helft, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 1;10 (13) :4363-8.|[2]Anthony W. Tolcher, et al. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol. 2003 Jan 15;21 (2) :211-22.